34.40
0.00
(0.00%)
At close: March 3 at 4:43:32 PM GMT+1
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
--
--
--
33,193
18,816
Operating Expense
252,054
252,054
171,295
167,563
148,737
Operating Income
-252,054
-252,054
-171,295
-134,370
-129,921
Other Income Expense
5,760
5,760
5,506
-132
-1,878
Pretax Income
-246,294
-246,294
-165,789
-134,502
-131,799
Net Income Common Stockholders
-246,294
-246,294
-165,789
-134,502
-131,799
Diluted NI Available to Com Stockholders
-246,294
-246,294
-165,789
-134,502
-131,799
Basic EPS
-2.47
--
-1.99
-2.26
-3.59
Diluted EPS
-2.47
--
-1.99
-2.26
-3.59
Basic Average Shares
99,838.10
--
83,347.09
59,611.66
36,711.83
Diluted Average Shares
99,838.10
--
83,347.09
59,611.66
36,711.83
Total Operating Income as Reported
-252,054
-252,054
-171,295
-134,370
-129,921
Total Expenses
252,054
252,054
171,295
167,563
148,737
Net Income from Continuing & Discontinued Operation
-246,294
-246,294
-165,789
-134,502
-131,799
Normalized Income
-246,294
-246,294
-165,789
-134,502
-131,799
EBIT
-252,054
-252,054
-171,295
-134,370
-129,921
EBITDA
-250,117
-250,117
-168,451
-131,384
-127,294
Reconciled Depreciation
1,937
1,937
2,844
2,986
2,627
Net Income from Continuing Operation Net Minority Interest
-246,294
-246,294
-165,789
-134,502
-131,799
Normalized EBITDA
-250,117
-250,117
-168,451
-131,384
-127,294
12/31/2021 - 9/25/2019
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
8AP.SG Agios Pharmaceuticals Inc
31.40
-4.27%
ISI.MU Ionis Pharmaceuticals Inc
31.83
+4.74%
ISI.F Ionis Pharmaceuticals, Inc.
31.80
+6.21%
1AEA.HA argenx SE
595.00
+0.85%
1AE.SG argenx SE
607.00
+3.51%
1AE.F argenx SE
600.20
+1.73%
VX1.F Vertex Pharmaceuticals Incorporated
466.05
+0.17%
BHVN Biohaven Ltd.
32.06
-13.77%
RVMD Revolution Medicines, Inc.
38.34
-5.89%
INCY Incyte Corporation
70.26
-4.41%